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Abstract
Aims: The current study reports clinical outcomes at three year follow-up of the LEADERS clinical trial 
which was the first all-comers trial comparing a new generation biodegradable polymer biolimus drug-elut-
ing stent (BES) with the first generation permanent polymer sirolimus-eluting stent (SES).
 
Methods and results: One thousand seven hundred and seven patients were randomised to unrestricted use 
of BES (n=857) or SES (n=850) in an all-comers population. Three year follow-up was available in 95% of 
the patients, 812 treated with BES and 809 treated with SES. At three years, BES remains non-inferior to SES 
for the primary endpoint of major adverse cardiac events (composite of cardiac death, myocardial infarction 
(MI), or clinically-indicated target vessel revascularisation (CI-TVR) (BES 15.7% versus SES 19%; HR 0.82 
CI 0.65-1.03; p=0.09). The MACE Kaplan Meier event curves increasingly diverge with the difference in 
events increasing from 1.4% to 2.4% and 3.3% at 1, 2 and 3 years, respectively in favour of BES. The rate of 
cardiac death was non-significantly lower 4.2% versus 5.2% (HR=0.81 CI 0.52-1.26; p=0.34) and the rate of 
myocardial infarction was equivalent 7.2% versus 7.1% (HR 1.01 CI 0.70-1.44; p=0.97) for BES versus SES, 
respectively. Thus BES was non-inferior to SES in all the safety endpoints. Clinically-indicated TVR occurred 
in 9.4% of BES treated patients versus 11.1% of SES treated patients (HR 0.84 CI 0.62-1.13; p=0.25). Rates 
of definite stent thrombosis were 2.2% for BES and 2.9% for SES (HR 0.78 CI 0.43-1.43; p=0.43), with the 
event rate increase of 0.2% from one to three years for BES and 0.9% for SES. For patients presenting with 
ST-elevation myocardial infarction BES was superior to SES in reducing MACE.
Conclusions: The findings of the three year follow-up support the claim that the biodegradable polymer biolimus-
eluting stent has equivalent safety and efficacy to permanent polymer sirolimus-eluting stent in an all-comers patient 
population. Its performance is superior in some subpopulations such as in ST-elevation MI patients and event rates for 
BES are overall lower than for SES with a trend toward increasing divergence of outcomes over three years.
KEYWORDS
•	 biolimus-eluting 
stent
•	 sirolimus-eluting 
stent
•	 angioplasty
n   
790
EuroIntervention 2
0
11
;7
:789-795
Introduction
Drug-eluting stents (DES) dubbed the third revolution in interventional 
cardiology (after balloon angioplasty and bare metal stents being first 
and second) have to a large degree solved the problem of in-stent reste-
nosis.1 However, the first generation devices such as sirolimus-eluting 
and paclitaxel-eluting stents with permanent polymer have relatively 
high rates of stent thrombosis, including very late stent thrombosis of 
up to 6% at five years in an all-comers unrestricted population (Bern-
Rotterdam).2 The reason for this high event rate is multifactorial but 
one of the prominent causes may be a hypersensitivity reaction and 
endothelial dysfunction caused by the permanent polymer from which 
the drug is eluted in the first generation DES.3,4
For this reason with the reduction of stent thrombosis in mind, 
Biomatrix Flex biolimus-eluting stent (BES) (Biosensors, Morges, 
Switzerland) was designed to elute biolimus from a polylactide 
(PLA) biodegradable polymer applied to the stent’s abluminal sur-
face.5 The polymer is fully metabolised to water and carbon dioxide 
within six to nine months from implantation leaving only the bare 
metal stainless steel platform behind. Biolimus is a semi-synthetic 
highly lipophilic inhibitor of the mammalian target of rapamycin, 
ten times as potent as sirolimus. BES has been shown to be non-
inferior to the sirolimus-eluting permanent polymer stent at 9 and 
12 months in terms of major adverse cardiac events in the all-comers 
LEADERS clinical trial.6 The current study is a report of three year 
outcomes of the first all-comers trial in an unrestricted population 
of BES versus SES with focus on special patient populations and 
very late definite stent thrombosis risk, especially in patients who 
have interrupted DAPT therapy.
Methods
STUDY POPULATION 
LEADERS was a multicentre European non-inferiority trial com-
paring the safety and efficacy of the BioMatrix™ Flex biolimus-
eluting stent with a biodegradable polymer (BES) (Biosensors, 
Morges, Switzerland) to the Cypher® SelectTM sirolimus-eluting 
stent with a durable polymer (SES) (Cordis, Warren, NJ, USA) in 
1,707 “all-comers” patients. The detailed study protocol can be 
found in the main publication.6 Briefly, patients included had 
chronic stable coronary artery disease or acute coronary syndromes 
including ST-elevation myocardial infarction, one of more lesions 
of >50% and a reference vessel diameter 2.25-3.5 mm. The only 
exclusion criteria were: known allergy to acetylsalicylic acid, clopi-
dogrel, heparin, stainless steel, sirolimus, biolimus or contrast that 
cannot be pre-medicated, planned surgery within six months of PCI 
unless DAPT could be continued through surgery, pregnancy or 
participation in another trial before reaching its primary endpoint. 
The study complied with the Declaration of Helsinki and was 
approved by all institutional ethics committees. All patients pro-
vided written, informed consent for participation in the trial.
RANDOMISATION AND PROCEDURES
Randomisation was performed centrally after diagnostic cardiac 
catheterisation and before percutaneous coronary intervention 
(PCI) by use of a telephone allocation service (Limburgia Tele-
fonische Antwoord Service BV, Rotterdam, The Netherlands). 
The allocation sequence was computer generated, stratified 
according to centre, and blocked with block sizes of 8 and 16, 
which varied randomly. We randomly allocated patients on a1:1 
basis to treatment with a BES or a SES and to active angiographic 
follow-up at nine months or clinical follow-up only on a 1:3 basis, 
with a factorial design.
BES were available in diameters of 2.25-3.5 mm and in 
lengths of 8-28 mm. SES were available in diameters of 2.25- 
3.5 mm and in lengths of 8-33 mm. We performed balloon angi-
oplasty and stent implantation according to standard technique 
and direct stenting was allowed. No mixture of drug-eluting 
stents was permitted within a given patient, unless the operator 
was unable to insert the study stent, in which case crossover to 
another device of the operator’s choice was possible. Before or 
at the time of the procedure, patients were given at least 75 mg 
of acetylsalicylic acid, 300-600 mg loading dose of clopidogrel, 
and unfractionated heparin at a dose of at least 5,000 I or 
70-100 IU/kg. After the procedure, all patients were advised to 
take aspirin indefinitely and clopidogrel for at least 12 months. 
In case of intercurrent revascularisation procedures requiring 
stent implantation, treating cardiologists were encouraged to use 
the study stent. For other details we refer to the primary end-
point publication.6 
STUDY ENDPOINTS
Definitions of all endpoints are provided elsewhere.6 The primary 
endpoint of this sub-study was MACE, defined as the composite of 
cardiac death, MI, and clinically-indicated target vessel revasculari-
sation (TVR) within 9-months. Secondary endpoints were any tar-
get lesion revascularisation (TLR) (both clinically and non-clinically 
indicated), any TVR, cardiac death, death from any cause, myocar-
dial infarction, stent thrombosis (defined according to the Aca-
demic Research Council)7,8, device success, and lesion success.
STATISTICS
The trial was powered for non-inferiority on the primary clinical 
endpoint. Continuous variables are expressed as mean+standard 
deviation and compared with student t-test. Categorical variables 
are presented as frequency (percentages) and compared using chi-
square test. Survival curves were constructed using Kaplan-Meier 
estimates, and compared by the log-rank test. The Mantel-Cox 
model was used for the rate ratios of clinical outcome. All analyses 
were performed using SAS 8.02 (SAS Institute Inc, Cary, NC, 
USA) by a dedicated statistician. All p-values and confidence inter-
vals were two-sided and p<0.05 was considered significant.
Results
FOLLOW-UP RATE AT THREE YEARS
Figure 1 flow chart summarises the follow-up rates at 1, 2 and 
3 years. Follow-up was available in 1,621 patients i.e., 95%. In the 
BES treated group 17 patients were lost to follow-up whereas 20 
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were lost to follow-up in the SES treated group. Eleven patients in 
each treatment arm withdrew consent.
PATIENT DEMOGRAPHICS AND LESION CHARACTERISTICS
The baseline clinical and angiographic characteristics are summa-
rised in Table 1, respectively. There were no significant differences 
between the two stent groups.
CLINICAL OUTCOMES AT 36 MONTHS (THREE YEARS)
At three years BES remained non-inferior to SES for the primary 
endpoint of major adverse cardiac events (composite of cardiac 
death, myocardial infarction (MI), or clinically-indicated target 
vessel revascularisation (TVR)) (BES 15.7% versus SES 19%; HR 
0.82 CI 0.65-1.03; p=0.09). The MACE Kaplan Meier event curves 
tend to increasingly diverge with the difference in events increasing 
from 1.4% to 2.4% and 3.3% at 1, 2 and 3 years, respectively in 
favour of BES (Figure 2A). The rate of cardiac death was non-sig-
nificantly lower 4.2% versus 5.2% (HR=0.81 CI 0.52-1.26; p=0.34; 
Figure 2B) and the rate of myocardial infarction was equivalent 
7.2% versus 7.1% (HR 1.01 CI 0.70-1.44; p=0.97; Figure 2C) for 
Randomised
(N=1,707)
BES (N=857)
BES (N=837)
BES (N=832)
BES (N=812)
SES (N=850)
SES (N=829)
SES (N=823)
SES (N=809)
1-year follow-up
(N=1,666; 97.6%)
2-year follow-up
(N=1,655; 97.0%)
3-year follow-up
(N=1,621; 95.0%)
Lost to F/U = 17
Patient withdrawal = 11
Other = 17
20 = Lost to F/U
11 = Patient withdrawal
10 = Other
Figure 1. Flow chart showing completeness of follow-up at 1, 2 and 
3 years.
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Figure 2. A. Kaplan Meier curve for MACE (cardiac death, myocardial infarction and target vessel revascularisation) rate at three years and 
Hazard ratios for superiority: BES (grey) versus SES (red). B. Kaplan Meier curve for cardiac death at three years.  C. Kaplan Meier curve 
for all myocardial infarctions at three years.  D. Kaplan Meier curve for target vessel revascularisation at three years.
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BES versus SES, respectively. Thus BES was non-inferior to SES 
in all the safety endpoints at three years (Figure 3A). Clinically-
indicated TVR occurred in 9.4% of BES treated patients versus 
11.1% of SES treated patients (HR 0.84 CI 0.62-1.13; p=0.25; 
Figure 2D). BES was non-inferior to SES in efficacy endpoints at 
three years (Figure 3B). 
SUBPOPULATIONS (PRE-SPECIFIED AND POST HOC)
The findings of the primary endpoint (MACE) were consistent across 
the pre-specified analyses for diabetes, acute coronary syndromes, 
de novo lesions, left anterior descending lesions, off-label use, small 
vessels and long-lesions except a significant interaction was observed 
between estimated HR and presence or absence of ST-elevation myo-
cardial infarction at baseline (HR 0.43; CI 0.22-0.83; p=0.01) (Fig-
ure 4). In addition, there was a trend to reduction in event rates with the 
use of BES in patients with multivessel disease (HR 0.65; CI 0.41-
1.03; p=0.06). Post hoc analysis of the highest SYNTAX score tertile 
patients (defined as SYNTAX score >16) showed significantly lower 
cardiac death for patients treated with BES (4.7% versus 10.5%; HR 
0.43; CI 0.21-0.89; p=0.02) (Figure 5).
STENT THROMBOSIS AND DAPT TREATMENT
Rates of definite stent thrombosis were 2.2% for BES and 2.9% 
for SES (HR 0.78 CI 0.43-1.43; p=0.43), with the event rate 
increase of 0.2% from one to three years for BES and 0.9% for 
SES (Figure 6). Table 2 summarises the rates of antiplatelet agent 
utilisation at 9, 12, 24 and 36 months which were not different in 
the BES and SES group (aspirin use of 94% and clopidogrel use 
of 20%). Among patients who discontinued DAPT before 12 
months, definite stent thrombosis occurred in four patients treated 
with SES and none treated with BES. Among patients who dis-
continued clopidogrel after 12 months, definite stent thrombosis 
occurred in two patients treated with SES and none treated with 
BES (Figure 7). 
Table 1. Baseline demographic and angiographic patient data.
Patient demographics
BES 
857 patients
SES 
850 patients
Age in years 65±11 65±11
Male gender 75% 75%
Arterial hypertension 74% 73%
Diabetes mellitus 26% 23%
insulin-dependent 10% 9%
Hypercholesterolaemia 65% 68%
Family history 40% 44%
Smoking 24% 25%
Previous MI 32% 33%
Previous PCI 36% 37%
with drug-eluting 12% 14%
Previous CABG 11% 13%
Chronic stable angina 45% 44%
Patient characteristics
Acute coronary syndrome 55% 56%
% Unstable angina 22% 21%
% Non-ST-elevation 17% 18%
% ST-S evation MI 16% 17%
Left ventricular ejection traction 56±11% 55±12%
Number of lesions per patient 1.5±0.7 1.4±0.7
Lesions per patient
% 1 lesion 63% 69%
% 2 lesions 29% 22%
% 3 lesions 7% 8%
% >4lesions 1% 2%
De novo lesions 92% 91%
Long lesions (>20 mm) 31% 27%
Small vessels (RVD <2.75 mm) 68% 67%
Off label use 81% 78%
Figure 3.  A) Three-year safety endpoints for BES versus SES showing equivalent safety (death, cardiac death, myocardial infarction, 
non-Q-wave myocardial infarction, Q-wave myocardial infarction and combined cardiac death or myocardial infarction. B) Three-year 
efficacy end-point for BES versus SES showing equivalent efficacy with a trend to lower TVR for BES (clinically indicated TLR, any TLR, 
clinically indicated TVR and any TVR).
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Figure 4. MACE rate for patients treated with BES versus SES stratified by pre-specified subgroups: diabetic patients, acute coronary 
syndrome at presentation, ST-elevation myocardial infarction at presentation, left anterior descending artery disease, multivessel disease, 
off-label use, de novo lesions, small vessels and long lesions. BES performs superiorly to DES in patients presenting with ST-elevation 
myocardial infarction.
 BES SES Risk ratio (95% CI) p value p test
Overall 132/857 157/850 0.80 (0.63 to 1.03)  ns
Diabetes mellitus     ns
Yes 53/223 45/191 1.02 (0.68 to 1.52) 0.92
No 79/634 112/659 0.72 (0.54 to 0.96) 0.02
Acute coronary     ns
Yes 68/470 87/473 0.77 (0.56 to 1.06) 0.11
No 64/387 70/377 0.88 (0.63 to 1.25) 0.48
ST-elevation MI     0.03
Yes 13/135 29/140 0.43 (0.22 to 0.83) 0.01
No 119/722 128/710 0.91 (0.71 to 1.18) 0.48
Left anterior     ns
Yes 59/407 71/417 0.84 (0.59 to 1.17) 0.32
No 73/449 86/431 0.81 (0.59 to 1.11) 0.18
Multivessel disease     ns
Yes 33/209 42/176 0.65 (0.41 to 1.03) 0.06
No 99/643 115/674 0.89 (0.68 to 1.16) 0.39
Off-label use     ns
Yes 116/696 135/665 0.81 (0.63 to 1.04) 0.09
No 16/160 22/183 0.83 (0.44 to 1.59) 0.58
De novo lesions     ns
Yes 114/788 136/774 0.82 (0.64 to 1.05) 0.11
No 18/68 21/74 0.92 (0.49 to 1.73) 0.79
Small-vessel disease     ns
Yes 96/535 104/568 0.89 (0.68 to 1.18) 0.43
No 36/271 53/280 0.68 (0.45 to 1.04) 0.08
Long lesions     ns
Yes 46/262 52/225 0.74 (0.50 to 1.10) 0.14
No 86/594 105/623 0.85 (0.64 to 1.13) 0.27
0.25 0.5 1 2 4
Figure 5. Cardiac death for patients in the highest tertile of the 
SYNTAX score is lower for patients treated with BES versus SES at 
three years (HR 0.43; p=0.02). 
1-year HR
0.40 (0.16 to 0.97)
p =0.042*
2-year HR
0.48 (0.23 to 0.99)
p =0.046*
3-year HR
0.43 (0.21 to 0.89)
p =0.02*
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Cardiac death for SYNTAX >16
Figure 6. Definite stent thrombosis rate at three years for patients 
treated with BES versus SES showing greater increases in very late 
events for SES.
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Discussion
This study confirms that biodegradable polymer biolimus-eluting 
stent (BES) is non-inferior to the permanent polymer sirolimus-
eluting stent (SES) at three year follow-up in the context of an unre-
stricted use in a randomised “all-comers” trial. The primary clinical 
endpoint of MACE (combined cardiac death, myocardial infarction 
and clinically indicated target vessel revascularisation) continues to 
show a lower event rate for patients treated with BES with incre-
mental benefit to the use of BES over SES and with a trend towards 
statistical significance. In addition, the subgroup analysis confirms 
that high-risk patients such as patients presenting with acute ST-
elevation myocardial infarction have better outcomes with BES 
treatment. Patients with a high SYNTAX score have a lower car-
diac death rate when treated with BES when compared to SES.9
The major strength of this trial is that it tested the performance of 
the new generation biodegradable polymer drug-eluting stent in a 
patient population that has close to an 80% off-label use as well as 
an increased risk of adverse events. It reflects the real clinical prac-
tice and therefore tests the device in the real-world setting.10 Thus in 
Figure 7. The effect of DAPT discontinuation before 12 months and 
after 12 months post-procedure on stent thrombosis events in patients 
treated with BES (no events) versus SES.
Overall population Patient who d/c DAPT
N=0/186 N=4/188 N=0/640 N=2/616
3 Y ST in LEADERS ST after DAPT 
d/c <12 m
ST after DAPT 
d/c >12 m
* p values for superiority (Fisher exact test)
3.0
2.5
2.0
1.5
1.0
0.5
0.0
%
2.2
2.9
2.4
0 0
0.4
BES    SES
p =0.12*
p =0.24*
Table 2. Antiplatelet agent utilisation at 9, 12, 24 and 36 months 
for patients treated with BES and SES.
BES SES p value
Aspirin
At 9 months 96.6% (n=818) 97.4% (n=798) 0.39
At 12 months 97.0% (n=810) 96.1% (n=801) 0.34
At 24 months 94.9% (n=789) 94.2% (n=778) 0.58
At 36 months 94.3% (n=757) 94.8% (n=745) 0.73
Clopidrogel/Thienopyridine
At 9 months 95.6% (n=818) 95.2% (n=798) 0.81
At 12 months 68.1% (n=810) 56.5% (n=801) 0.52
At 24 months 23.4% (n=789) 24.3% (n=778) 0.72
At 36 months 19.6% (n=757) 20.4% (n=747) 0.75
both treatment groups the event rates are overall higher than the 
ones reported from the initial DES trials and some of the more 
recent randomised trials such as ENDEAVOR IV and SPIRIT III in 
which simple de novo lesions were treated.11-14 In addition, while 
ENDEAVOR and SPIRIT used angiographically-driven outcomes 
(lesion-based and device-based analysis), LEADERS focused on 
patient-based clinical outcomes: all cardiac death, all MI and all 
clinically-driven TVR.
The use of the first generation drug-eluting stents has been asso-
ciated with an increased risk of stent thrombosis, an issue that was 
of particular importance in off-label indication cases.15 We show in 
this study that the biodegradable polymer BES has lower stent 
thrombosis rates than the permanent polymer stent of the first gen-
eration. The differences do not reach statistical significance as the 
trial has not been powered to detect them, and registry data with 
larger patient numbers or longer follow-up will be needed to con-
firm whether biodegradable polymer DES can reduce stent throm-
bosis rates. The Bern-Rotterdam registry shows that event rates 
steadily increase for sirolimus-eluting stents at 0.6% per year.2,16 
Similarly in ARTS-II overall stent thrombosis rate reaches 9.4% at 
five years for sirolimus stent treated patients.17 If the average very 
late definite stent thrombosis rate is 0.1% for BES and 0.6% for 
SES, one can project that the differences in stent thrombosis for 
BES versus SES may reach statistical significance. OCT analysis at 
nine months seems to suggest that biodegradable polymer bioli-
mus-eluting stent has better strut coverage than the permanent poly-
mer sirolimus-eluting stent.18 In addition, patients who stopped 
DAPT do not appear to have any additional events at three years in 
the BES arm while these events do accrue in the SES arm. 
Limitations
The study was performed in a tertiary care centre with high volume 
operators throughout Europe and thus the results might not be gen-
eralisable to low volume peripheral centres.
Conclusions
The findings of the three year follow-up support the claim that bio-
degradable polymer biolimus-eluting stent has equivalent safety 
and efficacy to permanent polymer sirolimus-eluting stent in an 
all-comers patient population. Its performance is superior in some 
subpopulations such as ST-elevation MI patients and event rates for 
BES are overall lower than for SES with increasing divergence of 
Kaplan Meier curves.
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